Prospective Grant of Exclusive License: Heat Induced Gene Expression to Treat Cancer, 39525-39526 [05-13446]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 130 / Friday, July 8, 2005 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Sensory
SBIRs.
Date: July 27, 2005.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Bernard F. Driscoll, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5184,
MSC 7844, Bethesda, MD 20892, (301) 435–
1242, driscolb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Chemoprevention of Lung Cancer.
Date: July 29, 2005.
Time: 10 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Eun Ah Cho, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6202,
MSC 7804, Bethesda, MD 20892, (301) 451–
4467, choe@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 29, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–13464 Filed 7–7–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Method for Diagnosis of
Atherosclerosis
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of an exclusive
license worldwide to practice the
invention embodied in: Provisional
Patent Application Serial No. 60/
607,031 filed 9/3/2004, and Provisional
Patent Application Serial No. 60/
618,275 filed 10/12/2004 titled ‘‘Method
for Diagnosis of Atherosclerosis’’
VerDate jul<14>2003
16:32 Jul 07, 2005
Jkt 205001
39525
referenced at HHS as E–276–2004/0–
US–01 and E–276–2004/0–US–01
respectively to Biosite, Inc., having a
place of business in the state of
California. The field of use may be
limited to an FDA approved clinical
diagnostic product for atherosclerosis.
The United States of America is the
assignee of the patent rights in this
invention. The territory may be
worldwide. This announcement is the
first notice to grant an exclusive license
to this technology.
Dated: June 30, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–13460 Filed 7–7–05; 8:45 am]
Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before
September 6, 2005 will be considered.
Prospective Grant of Exclusive
License: Heat Induced Gene
Expression to Treat Cancer
DATES:
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
ADDRESSES:
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
The
subject provisional patent applications
are related to the field of vascular
disease and markers expressed in
peripheral blood or secreted into serum.
Specifically, the claims are directed to
a method of diagnosing atherosclerosis
or determining the progression of
atherosclerosis in a subject by assaying
the expression of FOS, DUSP1, or both
FOS and DUSP1 in monocytes from the
subject wherein an increased expression
of either or both markers indicates
atherosclerosis or severity of
atherosclerosis in a subject.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. Provisional Patent
Application Serial No. 60/024,213,
entitled ‘‘Spatially And Temporal
Control Of Gene Expression Using A
Heat Shock Protein Promoter In
Combination With Local Heat’’ filed
August 15, 1996 (E–235–1995/0–US–
01), and all related foreign patents/
patent applications, to New England
OncoTherapeutics, Inc., having a place
of business in Cambridge,
Massachusetts. The patent rights in
these inventions have been assigned to
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to genebased therapeutics which incorporate
focused ultrasound heating technologies
to treat cancer.
DATES: Only written comments and/or
license applications that are received by
the National Institutes of Health on or
before September 6, 2005 will be
considered.
ADDRESSES: Requests for copies of the
patent, inquiries, comments and other
materials relating to the contemplated
exclusive license should be directed to:
George G. Pipia, Ph.D., Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–5560; Facsimile:
(301) 402–0220; E-mail:
pipiag@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
above-mentioned patent application
describes methods of using heat to
Requests for a copy of the
patent applications, inquiries,
comments and other materials relating
to the contemplated license should be
directed to: Fatima Sayyid, Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–4521; Facsimile:
(301) 402–0220; e-mail:
sayyidf@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
AGENCY:
E:\FR\FM\08JYN1.SGM
08JYN1
39526
Federal Register / Vol. 70, No. 130 / Friday, July 8, 2005 / Notices
control expression of specific genes in
genetically engineered tissues and
tumors. Therapeutic genes are put under
control of a heat-responsive promoter,
such as a promoter of a heat shock gene,
and then introduced into cells.
Expression of the therapeutic genes is
induced by heating the cells with
focused ultrasound or electromagnetic
radiation. When guided by MRI, it is
possible to heat small areas while
visualizing and quantitating the level of
heating. Thus, the technology could be
used to target specific tissues or tumors
for cancer therapy.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404.7. The
prospective exclusive license may be
granted unless within sixty (60) days
from the date of this published notice,
the NIH receives written evidence and
argument that establish that the grant of
the license would not be consistent with
the requirements of 35 U.S.C. 209 and
37 CFR part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
DC 20410; telephone (202) 708–1234;
TTY number for the hearing- and
speech-impaired (202) 708–2565, (these
telephone numbers are not toll-free), or
call the toll-free Title V information line
at 1–800–927–7588.
SUPPLEMENTARY INFORMATION: In
accordance with the December 12, 1988
court order in National Coalition for the
Homeless v. Veterans Administration,
No. 88–2503–OG (D.D.C.), HUD
publishes a Notice, on a weekly basis,
identifying unutilized, underutilized,
excess and surplus Federal buildings
and real property that HUD has
reviewed for suitability for use to assist
the homeless. Today’s Notice is for the
purpose of announcing that no
additional properties have been
determined suitable or unsuitable this
week.
Dated: June 28, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–13446 Filed 7–7–05; 8:45 am]
AGENCY:
BILLING CODE 4140–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–4980–N–27]
Federal Property Suitable as Facilities
To Assist the Homeless
Office of the Assistant
Secretary for Community Planning and
Development, HUD.
ACTION: Notice.
AGENCY:
SUMMARY: This Notice identifies
unutilized, underutilized, excess, and
surplus Federal property reviewed by
HUD for suitability for possible use to
assist the homeless.
EFFECTIVE DATE: July 8, 2005.
FUR FURTHER INFORMATION CONTACT:
Kathy Ezzell, Department of Housing
and Urban Development, Room 7262,
451 Seventh Street, SW., Washington,
VerDate jul<14>2003
16:32 Jul 07, 2005
Jkt 205001
Dated: June 30, 2005.
Mark R. Johnston,
Director, Office of Special Needs Assistance
Programs.
[FR Doc. 05–13309 Filed 7–7–05; 8:45 am]
BILLING CODE 4210–24–M
DEPARTMENT OF THE INTERIOR
Office of Surface Mining Reclamation
and Enforcement
Notice of Proposed Information
Collection for 1029–0054
Office of Surface Mining
Reclamation and Enforcement.
ACTION: Notice and request for
comments.
SUMMARY: In compliance with the
Paperwork Reduction Act of 1995, the
Office of Surface Mining Reclamation
and Enforcement (OSM) is announcing
that the information collection request
for 30 CFR 872, Abandoned mine
reclamation funds has been forwarded
to the Office of Management and Budget
(OMB) for review and reauthorization.
The information collection package was
previously approved and assigned
clearance numbers 1029–0054. This
notice describes the nature of the
information collection activity and the
expected burden and cost.
DATES: OMB has up to 60 days to
approve or disapprove the information
collection but may respond after 30
days. therefore, public comments
should be submitted to OMB by August
8, 2005, in order to be assured of
consideration.
ADDRESSES: Submit comments to the
Office of Information and Regulatory
Affairs, Office of Management and
Budget, Attention: Department of
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Interior Desk Officer, by telefax at (202)
395–6566 or via e-mail to
OIRA_Docket@omb.eop.gov. Also,
please send a copy of your comments to
John A. Trelease, Office of Surface
Mining Reclamation and Enforcement,
1951 Constitution Avenue, NW., Room
202—SIB, Washington, DC 20240, or
electronically to jtreleas@osmre.gov.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the information
collection requests, explanatory
information and related forms, contact
John A. Trelease at (202) 208–2783, or
electronically to jtreleas@osmre.gov.
SUPPLEMENTARY INFORMATION: The Office
of Management and Budget (OMB)
regulations at 5 CFR 1320, which
implement provisions of the Paperwork
Reduction Act of 1995 (Pub. L. 104–13),
require that interested members of the
public and affected agencies have an
opportunity to comment on information
collection and recordkeeping activities
[see 5 CFR 1320.8(d)]. OSM has
submitted a request to OMB to renew its
approval for the collection of
information for 30 CFR part 872,
Abandoned mine reclamation funds.
OSM is requesting a 3-year term of
approval for these information
collection activities.
An agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless it displays a currently valid OMB
control number. The OMB control
number for this collection of
information is listed in 30 CFR 872.10,
which is 1029–0054. As required under
5 CFR 1320.8(d), a Federal Register
notice soliciting comments on this
collection of information was published
on February 15, 2005 (70 FR 7759). No
comments were received. This notice
provides the public with an additional
30 days in which to comment on the
following information collection
activity:
Title: Abandoned mine reclamation
funds, 30 CFR part 872.
OMB Control Number: 1029–0054.
Summary: 30 CFR 872 establishes a
procedure whereby States and Indian
tribes submit written statements
announcing the State/Tribes decision
not to submit reclamation plans, and
therefore, will not be granted AML
funds.
Bureau Form Number: None.
Frequency of Collection: Once.
Description of Respondents: State and
Tribal abandoned mine land
reclamation agencies.
Total Annual Responses: 1.
Total Annual Burden Hours: 1.
Total Non-Wage Costs: $0.
Send comments on the need for the
collection of information for the
E:\FR\FM\08JYN1.SGM
08JYN1
]]>Agencies
[Federal Register Volume 70, Number 130 (Friday, July 8, 2005)]
[Notices]
[Pages 39525-39526]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-13446]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Heat Induced Gene
Expression to Treat Cancer
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR part 404.7(a)(1)(i), that the National Institutes of Health,
Department of Health and Human Services, is contemplating the grant of
an exclusive patent license to practice the inventions embodied in U.S.
Provisional Patent Application Serial No. 60/024,213, entitled
``Spatially And Temporal Control Of Gene Expression Using A Heat Shock
Protein Promoter In Combination With Local Heat'' filed August 15, 1996
(E-235-1995/0-US-01), and all related foreign patents/patent
applications, to New England OncoTherapeutics, Inc., having a place of
business in Cambridge, Massachusetts. The patent rights in these
inventions have been assigned to the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to gene-based therapeutics which
incorporate focused ultrasound heating technologies to treat cancer.
DATES: Only written comments and/or license applications that are
received by the National Institutes of Health on or before September 6,
2005 will be considered.
ADDRESSES: Requests for copies of the patent, inquiries, comments and
other materials relating to the contemplated exclusive license should
be directed to: George G. Pipia, Ph.D., Technology Licensing
Specialist, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 435-5560; Facsimile: (301) 402-0220; E-mail:
pipiag@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The above-mentioned patent application
describes methods of using heat to
[[Page 39526]]
control expression of specific genes in genetically engineered tissues
and tumors. Therapeutic genes are put under control of a heat-
responsive promoter, such as a promoter of a heat shock gene, and then
introduced into cells. Expression of the therapeutic genes is induced
by heating the cells with focused ultrasound or electromagnetic
radiation. When guided by MRI, it is possible to heat small areas while
visualizing and quantitating the level of heating. Thus, the technology
could be used to target specific tissues or tumors for cancer therapy.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404.7. The prospective exclusive license may be granted unless within
sixty (60) days from the date of this published notice, the NIH
receives written evidence and argument that establish that the grant of
the license would not be consistent with the requirements of 35 U.S.C.
209 and 37 CFR part 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: June 28, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-13446 Filed 7-7-05; 8:45 am]
BILLING CODE 4140-01-P
